Render Target: STATIC
Render Timestamp: 2025-03-20T10:41:19.136Z
Commit: 779953b12a5930618aae6aca7c87fb286faeb1d7
XML generation date: 2025-03-07 13:06:49.765
Product last modified at: 2025-01-01T09:05:32.331Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

NVP-BEZ235 #13101

    Product Information

    Product Usage Information

    NVP-BEZ235 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 1.065 ml DMF and warm to 75°C for 5 minutes. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 5 nM-500 nM for 2-24 hr.

    Storage

    Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 469.54 g/mol
    Purity >99%
    Activity Solubility: Soluble in DMF at 10 mg/ml with warming. Soluble in DMSO at 1.33 mg/ml with warming. Very poorly soluble in water and ethanol.
    Molecular Formula C30H23N5O
    CAS 915019-65-7
    Solubility Soluble in anhydrous DMF at 10mg/ml and DMSO at 1.33mg/ml.

    Background

    NVP-BEZ235 is a selective and potent dual inhibitor of PI3 kinase and mTOR Ser/Thr protein kinase. Research studies show that NVP-BEZ235 reversibly inhibits the catalytic activity of these kinases by competing with ATP at the ATP-binding site (1,2). Studies demonstrate that NVP-BEZ235 has anti-proliferative characteristics and induces cell cycle arrest during G0/G1 phase through inhibition of CDK4 and cyclin D3 (2,3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.